115 related articles for article (PubMed ID: 38821317)
1. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
[TBL] [Abstract][Full Text] [Related]
2. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhizic Acid Derivatives Bearing Amino Acid Residues in the Carbohydrate Part as Dengue Virus E Protein Inhibitors: Synthesis and Antiviral Activity.
Hour MJ; Chen Y; Lin CS; Baltina LA; Kan JY; Tsai YT; Kiu YT; Lai HC; Baltina LA; Petrova SF; Lin CW
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142222
[TBL] [Abstract][Full Text] [Related]
5. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
6. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
[TBL] [Abstract][Full Text] [Related]
9. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
[TBL] [Abstract][Full Text] [Related]
10. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
[TBL] [Abstract][Full Text] [Related]
11. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
Baig MH; Sharma T; Ahmad I; Abohashrh M; Alam MM; Dong JJ
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802860
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
[TBL] [Abstract][Full Text] [Related]
13. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
14. Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.
Ghosh AK; Yadav M; Iddum S; Ghazi S; Lendy EK; Jayashankar U; Beechboard SN; Takamatsu Y; Hattori SI; Aamano M; Higashi-Kuwata N; Mitsuya H; Mesecar AD
Eur J Med Chem; 2024 Mar; 267():116132. PubMed ID: 38335815
[TBL] [Abstract][Full Text] [Related]
15. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
17. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study.
Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S
Gene; 2024 Oct; 926():148620. PubMed ID: 38821329
[TBL] [Abstract][Full Text] [Related]
18. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
[TBL] [Abstract][Full Text] [Related]
19. Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19.
Biernacki K; Ciupak O; Daśko M; Rachon J; Flis D; Budka J; Inkielewicz-Stępniak I; Czaja A; Rak J; Demkowicz S
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290910. PubMed ID: 38093611
[TBL] [Abstract][Full Text] [Related]
20. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
